泛免疫炎症值对晚期结直肠癌患者贝伐珠单抗治疗疗效的预测价值OA
Predictive Value of Pan-Immune-Inflammation Value for Therapeutic Efficacy of Bevacizumab in Patients with Advanced Colorectal Cancer
目的:探讨泛免疫炎症值(PIV)对晚期结直肠癌(CRC)患者贝伐珠单抗治疗疗效的预测价值.方法:回顾性分析2020年6月至2023年2月我院收治的110例晚期CRC患者的临床资料.采用受试者工作特性(ROC)曲线评估PIV对晚期CRC患者贝伐珠单抗治疗疗效的预测价值,并根据截断值分为低PIV组(PIV<286.45,63例)和高PIV组(PIV≥286.45,47例).采用单因素及多因素Logistic逐步回归分析晚期CRC患者贝伐珠单抗治疗疗效的影响因素,并通过Kaplan-Meier法进行生存分析.结果:ROC 分析显示,PIV 预测晚期 CRC 患者贝伐珠单抗治疗疗效的曲线下面积(AUC)(95%CI)为 0.882(0.828～0.936),截断值为286.45,特异度为76.39%,灵敏度为91.25%.高PIV组低分化、淋巴结转移患者所占比例均高于低PIV组(P<0.05).高PIV组客观缓解率(ORR)、疾病控制率(DCR)均低于低PIV组(P<0.05或P<0.001).多因素分析显示,低分化(OR=2.208,95%CI:1.527～3.191)、肝转移(OR=2.259,95%CI:1.557～3.279)、淋巴结转移(OR=2.330,95%CI:1.603～3.388)、PIV≥286.45(OR=2.751,95%CI:1.812～4.177)是影响晚期 CRC患者贝伐珠单抗治疗 DCR的危险因素(P<0.001).生存分析显示,低PIV组无进展生存期(PFS)和总生存期(OS)均显著长于高PIV组(P<0.001).结论:PIV高水平与晚期CRC患者贝伐珠单抗治疗DCR和预后具有相关性,可作为潜在的预测标记物.
Objective To explore the predictive value of pan-immune-inflammation value(PIV)for the therapeutic efficacy of Bevacizumab in patients with advanced colorectal cancer(CRC).Methods Clinical data of 110 patients with advanced CRC admitted to our hospital from June 2020 to February 2023 were retro-spectively analyzed.Receiver operating characteristic(ROC)curve was applied to evaluate the predictive value of PIV for the therapeutic efficacy of Bevacizumab in patients with advanced CRC.According to the cut-off value,patients were divided into the low PIV group(PIV<286.45,63 cases)and the high PIV group(PIV≥286.45,47 cases).Univariate and multivariate stepwise Logistic regression analyses were performed to iden-tify the influencing factors of therapeutic effect of Bevacizumab in patients with advanced CRC,and survival analysis was performed by the Kaplan-Meier method.Results ROC analysis showed that the area under the curve(AUC)(95%CI)of PIV in predicting the therapeutic efficacy of Bevacizumab was 0.882(0.828-0.936),with a cut-off value of 286.45,specificity of 76.39%and sensitivity of 91.25%.The proportions of patients with poorly differentiated tumor and lymph node metastasis in the high PIV group were higher than those in the low PIV group(P<0.05).The objective response rate(ORR)and disease control rate(DCR)of the high PIV group were lower than those of the low PIV group(P<0.05 or P<0.001).Multivariate analysis demonstrated that poor differentiation(OR=2.208,95%CI:1.527-3.191),liver metastasis(OR=2.259,95%CI:1.557-3.279),lymph node metastasis(OR=2.330,95%CI:1.603-3.388)and PIV≥286.45(OR=2.751,95%CI:1.812-4.177)were independent risk factors influencing DCR of Bevacizumab treat-ment in patients with advanced CRC(P<0.001).Survival analysis revealed that progression-free survival(PFS)and overall survival(OS)were significantly longer in the low PIV group compared with the high PIV group(P<0.001).Conclusion High PIV is correlated with DCR and prognosis in patients with advanced CRC receiving Bevacizumab,and PIV can serve as a potential predictive biomarker.
朱红珍;邓国华;顾玉兰;丘佳明;曹薛弦;杨柳艺;刘苇;孔炯
南通大学附属常熟医院 肿瘤科(江苏 常熟 215500)南通大学附属常熟医院 麻醉科(江苏 常熟 215500)南通大学附属常熟医院 肿瘤科(江苏 常熟 215500)南通大学附属常熟医院 病理科(江苏 常熟 215500)南通大学附属常熟医院 肿瘤科(江苏 常熟 215500)南通大学附属常熟医院 肿瘤科(江苏 常熟 215500)南通大学附属常熟医院 肿瘤科(江苏 常熟 215500)南通大学附属常熟医院 肿瘤科(江苏 常熟 215500)
泛免疫炎症值晚期结直肠癌贝伐珠单抗疗效
Pan-immune-inflammation valueAdvanced colorectal cancerBevacizumabTherapeutic efficacy
《中国肛肠病杂志》 2026 (8)
21-25,5
苏州市科技计划项目(SLT2023007)常熟市卫生健康委员会科技计划资助性项目暨常熟市科技发展计划(医疗卫生)指导性项目(CSWS202311)
评论